Differential expression of cyclooxygenase-2 in metastatic melanoma affects progression free survival

Elisabetta Panza, Paola De Cicco, Giuseppe Ercolano, Chiara Armogida, Giosuè Scognamiglio, Anna Maria Anniciello, Gerardo Botti, Giuseppe Cirino, Angela Ianaro

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

The possible correlation between cyclooxygenase-2 (COX-2) expression and disease progression in melanoma is still a matter of debate. Analysis of COX- 2 expression in 45 lymph node melanoma metastases demonstrates a significant correlation between the percent of expression and progression free survival (PFS). A positive COX-2 expression ≤10% (COX-2high), as opposite to a positive expression ≥9% (COX-2low), translated into a striking significant reduction of PFS of about 3 years. The reduction in PFS correlated neither with BRAFV600E nor with NRASQ61 expression in the analyzed samples. This concept was reinforced by the finding that tumour development in COX-2-/- mice was almost blunted. Similarly, inhibition of COX-2 protein expression in human melanoma cell lines, by using siRNAs technology as well as selective inhibition of COX-2 activity by celecoxib, reduced cellular proliferation and invasiveness. In conclusion we show that COX-2high is a negative prognostic factor in metastatic melanoma. Our study also clarifies that the uncertainty about the role of COX-2 in metastatic malignant melanoma, found in the current relevant literature, is probably due to the fact that a threshold in COX-2 expression has to be reached in order to impact on cancer malignancy. Our findings suggest that COX-2 expression may become an useful diagnostic tool in defining melanoma malignancy as well as argue for a possible therapeutic use of NSAID as add on therapy in selected cases.

Original languageEnglish
Pages (from-to)57077-57085
Number of pages9
JournalOncotarget
Volume7
Issue number35
DOIs
Publication statusPublished - 2016

Fingerprint

Cyclooxygenase 2
Disease-Free Survival
Melanoma
Celecoxib
Neoplasms
Non-Steroidal Anti-Inflammatory Agents
Therapeutic Uses
Uncertainty
Disease Progression
Lymph Nodes
Cell Proliferation
Neoplasm Metastasis
Technology
Cell Line
Proteins

Keywords

  • COX-2 mice
  • Cyclooxygenase-2
  • Malignant melanoma
  • Metastasis
  • Progression free survival

ASJC Scopus subject areas

  • Oncology

Cite this

Differential expression of cyclooxygenase-2 in metastatic melanoma affects progression free survival. / Panza, Elisabetta; Cicco, Paola De; Ercolano, Giuseppe; Armogida, Chiara; Scognamiglio, Giosuè; Anniciello, Anna Maria; Botti, Gerardo; Cirino, Giuseppe; Ianaro, Angela.

In: Oncotarget, Vol. 7, No. 35, 2016, p. 57077-57085.

Research output: Contribution to journalArticle

Panza, Elisabetta ; Cicco, Paola De ; Ercolano, Giuseppe ; Armogida, Chiara ; Scognamiglio, Giosuè ; Anniciello, Anna Maria ; Botti, Gerardo ; Cirino, Giuseppe ; Ianaro, Angela. / Differential expression of cyclooxygenase-2 in metastatic melanoma affects progression free survival. In: Oncotarget. 2016 ; Vol. 7, No. 35. pp. 57077-57085.
@article{88bac57a01e149fb8bcaf7616fce9a96,
title = "Differential expression of cyclooxygenase-2 in metastatic melanoma affects progression free survival",
abstract = "The possible correlation between cyclooxygenase-2 (COX-2) expression and disease progression in melanoma is still a matter of debate. Analysis of COX- 2 expression in 45 lymph node melanoma metastases demonstrates a significant correlation between the percent of expression and progression free survival (PFS). A positive COX-2 expression ≤10{\%} (COX-2high), as opposite to a positive expression ≥9{\%} (COX-2low), translated into a striking significant reduction of PFS of about 3 years. The reduction in PFS correlated neither with BRAFV600E nor with NRASQ61 expression in the analyzed samples. This concept was reinforced by the finding that tumour development in COX-2-/- mice was almost blunted. Similarly, inhibition of COX-2 protein expression in human melanoma cell lines, by using siRNAs technology as well as selective inhibition of COX-2 activity by celecoxib, reduced cellular proliferation and invasiveness. In conclusion we show that COX-2high is a negative prognostic factor in metastatic melanoma. Our study also clarifies that the uncertainty about the role of COX-2 in metastatic malignant melanoma, found in the current relevant literature, is probably due to the fact that a threshold in COX-2 expression has to be reached in order to impact on cancer malignancy. Our findings suggest that COX-2 expression may become an useful diagnostic tool in defining melanoma malignancy as well as argue for a possible therapeutic use of NSAID as add on therapy in selected cases.",
keywords = "COX-2 mice, Cyclooxygenase-2, Malignant melanoma, Metastasis, Progression free survival",
author = "Elisabetta Panza and Cicco, {Paola De} and Giuseppe Ercolano and Chiara Armogida and Giosu{\`e} Scognamiglio and Anniciello, {Anna Maria} and Gerardo Botti and Giuseppe Cirino and Angela Ianaro",
year = "2016",
doi = "10.18632/oncotarget.10976",
language = "English",
volume = "7",
pages = "57077--57085",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "35",

}

TY - JOUR

T1 - Differential expression of cyclooxygenase-2 in metastatic melanoma affects progression free survival

AU - Panza, Elisabetta

AU - Cicco, Paola De

AU - Ercolano, Giuseppe

AU - Armogida, Chiara

AU - Scognamiglio, Giosuè

AU - Anniciello, Anna Maria

AU - Botti, Gerardo

AU - Cirino, Giuseppe

AU - Ianaro, Angela

PY - 2016

Y1 - 2016

N2 - The possible correlation between cyclooxygenase-2 (COX-2) expression and disease progression in melanoma is still a matter of debate. Analysis of COX- 2 expression in 45 lymph node melanoma metastases demonstrates a significant correlation between the percent of expression and progression free survival (PFS). A positive COX-2 expression ≤10% (COX-2high), as opposite to a positive expression ≥9% (COX-2low), translated into a striking significant reduction of PFS of about 3 years. The reduction in PFS correlated neither with BRAFV600E nor with NRASQ61 expression in the analyzed samples. This concept was reinforced by the finding that tumour development in COX-2-/- mice was almost blunted. Similarly, inhibition of COX-2 protein expression in human melanoma cell lines, by using siRNAs technology as well as selective inhibition of COX-2 activity by celecoxib, reduced cellular proliferation and invasiveness. In conclusion we show that COX-2high is a negative prognostic factor in metastatic melanoma. Our study also clarifies that the uncertainty about the role of COX-2 in metastatic malignant melanoma, found in the current relevant literature, is probably due to the fact that a threshold in COX-2 expression has to be reached in order to impact on cancer malignancy. Our findings suggest that COX-2 expression may become an useful diagnostic tool in defining melanoma malignancy as well as argue for a possible therapeutic use of NSAID as add on therapy in selected cases.

AB - The possible correlation between cyclooxygenase-2 (COX-2) expression and disease progression in melanoma is still a matter of debate. Analysis of COX- 2 expression in 45 lymph node melanoma metastases demonstrates a significant correlation between the percent of expression and progression free survival (PFS). A positive COX-2 expression ≤10% (COX-2high), as opposite to a positive expression ≥9% (COX-2low), translated into a striking significant reduction of PFS of about 3 years. The reduction in PFS correlated neither with BRAFV600E nor with NRASQ61 expression in the analyzed samples. This concept was reinforced by the finding that tumour development in COX-2-/- mice was almost blunted. Similarly, inhibition of COX-2 protein expression in human melanoma cell lines, by using siRNAs technology as well as selective inhibition of COX-2 activity by celecoxib, reduced cellular proliferation and invasiveness. In conclusion we show that COX-2high is a negative prognostic factor in metastatic melanoma. Our study also clarifies that the uncertainty about the role of COX-2 in metastatic malignant melanoma, found in the current relevant literature, is probably due to the fact that a threshold in COX-2 expression has to be reached in order to impact on cancer malignancy. Our findings suggest that COX-2 expression may become an useful diagnostic tool in defining melanoma malignancy as well as argue for a possible therapeutic use of NSAID as add on therapy in selected cases.

KW - COX-2 mice

KW - Cyclooxygenase-2

KW - Malignant melanoma

KW - Metastasis

KW - Progression free survival

UR - http://www.scopus.com/inward/record.url?scp=84984917767&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84984917767&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.10976

DO - 10.18632/oncotarget.10976

M3 - Article

VL - 7

SP - 57077

EP - 57085

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 35

ER -